Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes

Mark E. Dudley(National Cancer Institute), John R. Wunderlich(National Cancer Institute), Paul F. Robbins(National Cancer Institute), James Chih‐Hsin Yang(National Cancer Institute), Patrick Hwu(National Cancer Institute), Douglas J. Schwartzentruber(National Cancer Institute), Suzanne L. Topalian(National Cancer Institute), Richard M. Sherry(National Cancer Institute), Nicholas P. Restifo(National Cancer Institute), Amy M. Hubicki(National Cancer Institute), Michael R. Robinson(National Eye Institute), Mark Raffeld(National Institutes of Health), Paul H. Duray(National Institutes of Health), Claudia A. Seipp(National Cancer Institute), Linda Rogers-Freezer(National Cancer Institute), Kathleen E. Morton(National Cancer Institute), Sharon Mavroukakis(National Cancer Institute), Donald E. White(National Cancer Institute), Steven A. Rosenberg(National Cancer Institute)
Science
October 24, 2002
Cited by 2,809Open Access
Full Text

Abstract

We report here the adoptive transfer, to patients with metastatic melanoma, of highly selected tumor-reactive T cells directed against overexpressed self-derived differentiation antigens after a nonmyeloablative conditioning regimen. This approach resulted in the persistent clonal repopulation of T cells in those cancer patients, with the transferred cells proliferating in vivo, displaying functional activity, and trafficking to tumor sites. This led to regression of the patients' metastatic melanoma as well as to the onset of autoimmune melanocyte destruction. This approach presents new possibilities for the treatment of patients with cancer as well as patients with human immunodeficiency virus-related acquired immunodeficiency syndrome and other infectious diseases.


Related Papers

No related papers found

Powered by citation graph analysis